Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population

Airoldi, Mario; Gabriele, Anna Maria; Garzaro, Massimiliano; Raimondo, Luca; Condello, Cecilia; Beatrice, Fabio; Pecorari, Giancarlo; Giordano, Carlo

doi:10.1016/j.radonc.2009.02.005

Cited by 28 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our neoadjuvant scheme has achieved a percentage of CR (33%) similar to the one reported by our group with a cisplatin+epirubicin combination [9] in a superimpose able group of patients.…”

Section: Discussionsupporting

confidence: 82%

“…We have published our previous experience with induction cisplatin plus epirubicin followed by conventional radiotherapy plus every 3 week cisplatin administration [9]; our results confirm the high activity of this approach in a non-endemic population.…”

Section: Introductionsupporting

confidence: 70%

“…According to our previously reported experience in a very similar series [9] we can draw the following conclusions: 17 1) NACT with carboplatin and taxol is very well tolerated with a clinical impact superimpose able to cisplatin + epirubicin;…”

Section: Discussionmentioning

confidence: 76%

“…Five recently published studies [6][7][8][9] have shown that induction CHT followed by CRT obtained high responses in patients coming from both endemic and non endemic areas: in two trials the authors proposed a three-drugs induction scheme, while in the others cisplatin + epirubicin or paclitaxel and carboplatin were respectively administered.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma

Airoldi

Gabriele

et al. 2010

Cancer Chemother Pharmacol

Self Cite

View full text Add to dashboard Cite

Methods: Thirty patients were treated with three cycles of carboplatin (AUC6) plus taxol (175mg/m 2 ) on day 1 every 3 weeks, followed by weekly carboplatin (AUC1) plus Taxol (60mg/m2) and concomitant radiotherapy (70Gy). Results:We observed the objective complete response rates of 33% (after chemotherapy) and 87%(after chemo-radiotherapy). Treatment tolerability and toxicity were controllable. Three and five years progression free survival were 80% and 75% respectively and 3 and 5 years overall survival were 85% and 80% (follow-up 49.5 months). Five years loco-regional control was 90.3% and five years distant metastases free survival was 85%.Conclusions: Neoadjuvant-chemotherapy with such protocol represents a feasible, efficient treatment for patients with A-NPC, ensuring excellent locoregional disease control and overall survival with low incidence of distant metastases.

show abstract

“…Our neoadjuvant scheme has achieved a percentage of CR (33%) similar to the one reported by our group with a cisplatin+epirubicin combination [9] in a superimpose able group of patients.…”

Section: Discussionsupporting

confidence: 82%

Section: Introductionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma

Airoldi

Gabriele

et al. 2010

Cancer Chemother Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Anthracycline has been used in combination with platinum agents in adult studies for NPC. 10 Our report suggests that the combination of oxaliplatin and doxorubicin may be effective in recurrent NPC that has been previously treated with cisplatin. High rates of secondary malignant neoplasms, sensorineural hearing loss, and other morbidities have been reported in children who receive RT for NPC.…”

Section: Discussionmentioning

confidence: 72%

Successful Treatment of Recurrent Metastatic Nasopharyngeal Carcinoma With Oxaliplatin and Doxorubicin

Venkatramani

Mascarenhas²

2014

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a rare tumor in children and often presents as advanced-stage disease. NPC in children is treated with neoadjuvant chemotherapy and radiotherapy. The prognosis for children who relapse after treatment is extremely poor. This report describes the successful treatment and long-term disease-free survival of a 16-year-old male patient with a history of stage IVA NPC, who recurred with pulmonary and hepatic metastases. The patient was treated with a novel combination of oxaliplatin and doxorubicin without irradiation.

show abstract

Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment

et al. 2018

View full text Add to dashboard Cite

show abstract

Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population

Cited by 28 publications

References 21 publications

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma

Successful Treatment of Recurrent Metastatic Nasopharyngeal Carcinoma With Oxaliplatin and Doxorubicin

Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment

Contact Info

Product

Resources

About